Novozymes' Veltis® half-life extension technology embraced by Paras Biopharmaceuticals to develop new biobetter

Paras Biopharmaceuticals partners with Novozymes in a feasibility study using VELTIS® technology to develop an improved version of a leading osteoporosis treatment.

Novozymes Biopharma and Paras Biopharmaceuticals will collaborate to generate an improved version – a biobetter - of Teriparatide, a leading treatment for osteoporosis, a debilitating bone disease largely affecting women over 50 years of age.

“The collective strengths of Paras Biopharmaceuticals’ and Novozymes’ technical expertise will bring solutions and treatment options to help osteoporosis patients”, says Dr Hans Söderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals Finland Oy. “Novozymes’ VELTIS technology and Paras Biopharmaceuticals’ Diabrid NobleCleav technology will create a superior osteoporosis medicine”, adds Dr. Ashesh Kumar, Director of Biologics and Licensing at Paras Biopharmaceuticals Finland Oy.

Further market validation
Already well-established in the fields of diabetes, hemophilia and neutropenia, the VELTIS platform provides once-weekly, once bi-weekly or once-monthly peptide or protein dosing. As a result, VELTIS offers the potential for enhanced patient adherence and improved therapeutic impact.

“This is further market validation of the Novozymes Biopharma’s VELTIS technology”, says Svend Licht, Director at Novozymes Biopharma. “The versatile capabilities of our solution are being continually demonstrated by our customers. We are happy to enable the development of this biobetter, in addition to running numerous collaborations in life cycle management and new drug candidates.”

The agreement is not expected to impact Novozymes’ financial expectations for 2015.
About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow.

About Paras Biopharmaceuticals Finland Oy

Based in Oulu, Finland, Paras Biopharmaceuticals is an award winning, privately-held Finnish company focused on developing biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. The company’s facilities (European GMP US-FDA compliant) in Finland are dedicated to the development, scale-up and GMP production of recombinant products for osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes) and oncology, in addition to high value recombinant enzymes such as Enterokinase (and other enzymes in pipeline). Paras Biopharmaceuticals has successfully developed its Diabrid Technology Platform (Diabrid® Technology, NobleCleav® Technolgy and Biomultifold® Microbial High Expression Technolgy) for the high level expression of biosimilars in specially designed genetically stable clones.
VELTIS is a clinically-proven technology based on engineered albumins delivered to allow the drug developer to optimize dose size and frequency to achieve stricter patient adherence (compliance) for improved therapeutic impact by targeting once weekly, once bi-weekly, or once monthly dosing.

VELTIS is delivered by Novozymes Biopharma and is provided with access to our extensive technical and regulatory support as well as to partner providers. The technology is well-established in the fields of diabetes, haemophilia and neutropenia by our customers.

Today, Novozymes Biopharma is working together with a number of pharma companies who are exploring the possibilities of VELTIS as a platform for half-life extension.  These companies include CSL and Teva, while GlaxoSmithKline is using VELTIS in a marketed drug for treatment of diabetes.
For further information please contact:
René Tronborg: